By blocking the interaction between PD-1 and its ligands PD-L1/PD-L2 on tumor cells, it alleviates the immunosuppressive effects of the tumor microenvironment, thereby restoring T cells’ ability to recognize and eliminate tumor cells (2, 3). The gene discussed is PDCD1LG2; the disease is neoplasm.